Migraine Drugs Market Research Report By Drug Type (Abortive Drugs, Preventive Drugs, CGRP Inhibitors, Triptans), By Route of Administration (Oral, Injectable, Nasal), By Therapeutic Class (NSAIDs, Ergots, Beta Blockers, Antidepressants), By Patient Demographics (Adults, Children, Geriatrics) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)- Forecast to 2035

TABLE OF CONTENTS




1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook



2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation



4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis



6. MIGRAINE DRUGS MARKET, BY DRUG TYPE (USD BILLION)
6.1. Abortive Drugs
6.2. Preventive Drugs
6.3. CGRP Inhibitors
6.4. Triptans
7. MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION (USD BILLION)
7.1. Oral
7.2. Injectable
7.3. Nasal
8. MIGRAINE DRUGS MARKET, BY THERAPEUTIC CLASS (USD BILLION)
8.1. NSAIDs
8.2. Ergots
8.3. Beta Blockers
8.4. Antidepressants
9. MIGRAINE DRUGS MARKET, BY PATIENT DEMOGRAPHICS (USD BILLION)
9.1. Adults
9.2. Children
9.3. Geriatrics
10. MIGRAINE DRUGS MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA



11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the Migraine Drugs Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Migraine Drugs Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. Pfizer
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. Selecta Biosciences
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. Alder BioPharmaceuticals
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. H. Lundbeck
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. AbbVie
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. Eli Lilly
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12.6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. Boehringer Ingelheim
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. GSK
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. Teva Pharmaceutical Industries
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. Eisai
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. Novartis
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Zogenix
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. F. HoffmannLa Roche
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. Bausch Health Companies
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies
12.15. Amgen
12.15.1. Financial Overview
12.15.2. Products Offered
12.15.3. Key Developments
12.15.4. SWOT Analysis
12.15.5. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES

TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 3. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 4. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 5. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 6. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 7. US MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 8. US MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 9. US MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 10. US MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 11. US MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 12. CANADA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 13. CANADA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 14. CANADA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 15. CANADA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 16. CANADA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 17. EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 18. EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 19. EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 20. EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 21. EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 22. GERMANY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 23. GERMANY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 24. GERMANY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 25. GERMANY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 26. GERMANY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 27. UK MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 28. UK MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 29. UK MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 30. UK MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 31. UK MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 32. FRANCE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 33. FRANCE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 34. FRANCE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 35. FRANCE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 36. FRANCE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 37. RUSSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 38. RUSSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 39. RUSSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 40. RUSSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 41. RUSSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 42. ITALY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 43. ITALY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 44. ITALY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 45. ITALY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 46. ITALY MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 47. SPAIN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 48. SPAIN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 49. SPAIN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 50. SPAIN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 51. SPAIN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 52. REST OF EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 53. REST OF EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 54. REST OF EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 55. REST OF EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 56. REST OF EUROPE MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 57. APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 58. APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 59. APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 60. APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 61. APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 62. CHINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 63. CHINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 64. CHINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 65. CHINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 66. CHINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 67. INDIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 68. INDIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 69. INDIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 70. INDIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 71. INDIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 72. JAPAN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 73. JAPAN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 74. JAPAN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 75. JAPAN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 76. JAPAN MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 77. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 78. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 79. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 80. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 81. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 82. MALAYSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 83. MALAYSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 84. MALAYSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 85. MALAYSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 86. MALAYSIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 87. THAILAND MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 88. THAILAND MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 89. THAILAND MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 90. THAILAND MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 91. THAILAND MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 92. INDONESIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 93. INDONESIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 94. INDONESIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 95. INDONESIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 96. INDONESIA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 97. REST OF APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 98. REST OF APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 99. REST OF APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 100. REST OF APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 101. REST OF APAC MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 102. SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 103. SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 104. SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 105. SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 106. SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 107. BRAZIL MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 108. BRAZIL MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 109. BRAZIL MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 110. BRAZIL MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 111. BRAZIL MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 112. MEXICO MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 113. MEXICO MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 114. MEXICO MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 115. MEXICO MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 116. MEXICO MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 117. ARGENTINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 118. ARGENTINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 119. ARGENTINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 120. ARGENTINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 121. ARGENTINA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 122. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 123. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 124. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 125. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 126. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 127. MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 128. MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 129. MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 130. MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 131. MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 132. GCC COUNTRIES MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 133. GCC COUNTRIES MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 134. GCC COUNTRIES MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 135. GCC COUNTRIES MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 136. GCC COUNTRIES MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 137. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 138. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 139. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 140. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 141. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 142. REST OF MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD BILLIONS)
TABLE 143. REST OF MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 144. REST OF MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
TABLE 145. REST OF MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD BILLIONS)
TABLE 146. REST OF MEA MIGRAINE DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 148. ACQUISITION/PARTNERSHIP





























LIST OF FIGURES

FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA MIGRAINE DRUGS MARKET ANALYSIS
FIGURE 3. US MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 4. US MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 5. US MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 6. US MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 7. US MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 8. CANADA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 9. CANADA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 10. CANADA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 11. CANADA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 12. CANADA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 13. EUROPE MIGRAINE DRUGS MARKET ANALYSIS
FIGURE 14. GERMANY MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 15. GERMANY MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 16. GERMANY MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 17. GERMANY MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 18. GERMANY MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 19. UK MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 20. UK MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 21. UK MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 22. UK MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 23. UK MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 24. FRANCE MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 25. FRANCE MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 26. FRANCE MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 27. FRANCE MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 28. FRANCE MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 29. RUSSIA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 30. RUSSIA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 31. RUSSIA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 32. RUSSIA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 33. RUSSIA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 34. ITALY MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 35. ITALY MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 36. ITALY MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 37. ITALY MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 38. ITALY MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 39. SPAIN MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 40. SPAIN MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 41. SPAIN MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 42. SPAIN MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 43. SPAIN MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 44. REST OF EUROPE MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 45. REST OF EUROPE MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 46. REST OF EUROPE MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 47. REST OF EUROPE MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 48. REST OF EUROPE MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 49. APAC MIGRAINE DRUGS MARKET ANALYSIS
FIGURE 50. CHINA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 51. CHINA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 52. CHINA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 53. CHINA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 54. CHINA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 55. INDIA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 56. INDIA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 57. INDIA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 58. INDIA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 59. INDIA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 60. JAPAN MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 61. JAPAN MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 62. JAPAN MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 63. JAPAN MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 64. JAPAN MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 65. SOUTH KOREA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 66. SOUTH KOREA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 67. SOUTH KOREA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 68. SOUTH KOREA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 69. SOUTH KOREA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 70. MALAYSIA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 71. MALAYSIA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 72. MALAYSIA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 73. MALAYSIA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 74. MALAYSIA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 75. THAILAND MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 76. THAILAND MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 77. THAILAND MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 78. THAILAND MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 79. THAILAND MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 80. INDONESIA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 81. INDONESIA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 82. INDONESIA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 83. INDONESIA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 84. INDONESIA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 85. REST OF APAC MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 86. REST OF APAC MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 87. REST OF APAC MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 88. REST OF APAC MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 89. REST OF APAC MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 90. SOUTH AMERICA MIGRAINE DRUGS MARKET ANALYSIS
FIGURE 91. BRAZIL MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 92. BRAZIL MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 93. BRAZIL MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 94. BRAZIL MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 95. BRAZIL MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 96. MEXICO MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 97. MEXICO MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 98. MEXICO MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 99. MEXICO MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 100. MEXICO MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 101. ARGENTINA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 102. ARGENTINA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 103. ARGENTINA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 104. ARGENTINA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 105. ARGENTINA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 106. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 107. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 108. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 109. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 110. REST OF SOUTH AMERICA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 111. MEA MIGRAINE DRUGS MARKET ANALYSIS
FIGURE 112. GCC COUNTRIES MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 113. GCC COUNTRIES MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 114. GCC COUNTRIES MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 115. GCC COUNTRIES MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 116. GCC COUNTRIES MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 117. SOUTH AFRICA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 118. SOUTH AFRICA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 119. SOUTH AFRICA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 120. SOUTH AFRICA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 121. SOUTH AFRICA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 122. REST OF MEA MIGRAINE DRUGS MARKET ANALYSIS BY DRUG TYPE
FIGURE 123. REST OF MEA MIGRAINE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 124. REST OF MEA MIGRAINE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS
FIGURE 125. REST OF MEA MIGRAINE DRUGS MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
FIGURE 126. REST OF MEA MIGRAINE DRUGS MARKET ANALYSIS BY REGIONAL
FIGURE 127. KEY BUYING CRITERIA OF MIGRAINE DRUGS MARKET
FIGURE 128. RESEARCH PROCESS OF MRFR
FIGURE 129. DRO ANALYSIS OF MIGRAINE DRUGS MARKET
FIGURE 130. DRIVERS IMPACT ANALYSIS: MIGRAINE DRUGS MARKET
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: MIGRAINE DRUGS MARKET
FIGURE 132. SUPPLY / VALUE CHAIN: MIGRAINE DRUGS MARKET
FIGURE 133. MIGRAINE DRUGS MARKET, BY DRUG TYPE, 2025 (% SHARE)
FIGURE 134. MIGRAINE DRUGS MARKET, BY DRUG TYPE, 2019 TO 2035 (USD Billions)
FIGURE 135. MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2025 (% SHARE)
FIGURE 136. MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019 TO 2035 (USD Billions)
FIGURE 137. MIGRAINE DRUGS MARKET, BY THERAPEUTIC CLASS, 2025 (% SHARE)
FIGURE 138. MIGRAINE DRUGS MARKET, BY THERAPEUTIC CLASS, 2019 TO 2035 (USD Billions)
FIGURE 139. MIGRAINE DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2025 (% SHARE)
FIGURE 140. MIGRAINE DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2019 TO 2035 (USD Billions)
FIGURE 141. MIGRAINE DRUGS MARKET, BY REGIONAL, 2025 (% SHARE)
FIGURE 142. MIGRAINE DRUGS MARKET, BY REGIONAL, 2019 TO 2035 (USD Billions)
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS